Financial TimesUS approves Alzheimer's drug that slows rate of cognitive declineJan 6, 2023Jamie SmythBy Jamie Smythmore_vert
The Associated PressEXPLAINER: New drug slows Alzheimer's but comes with caveatsJan 7, 2023Lauran Neergaard & Matthew PerroneBy Lauran Neergaard & Matthew Perronemore_vert
CNBCFDA approves Alzheimer's drug that slowed cognitive decline in clinical trialJan 6, 2023Spencer KimballBy Spencer Kimballmore_vert
PR NewswireEISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI™ (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S ...Jan 6, 2023more_vert
ReutersEisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for full approvalJan 7, 2023Julie Steenhuysen & Deena BeasleyBy Julie Steenhuysen & Deena Beasleymore_vert
The New York TimesFDA Approves, Leqembi, New Treatment for Early Alzheimer’sJan 6, 2023Pam BelluckBy Pam Belluckmore_vert
The Wall Street JournalNew Alzheimer's Drug Approved by FDA, Promises to Slow DiseaseJan 6, 2023Joseph WalkerBy Joseph Walkermore_vert
The Guardian USFDA approves breakthrough Alzheimer’s drug LecanemabJan 6, 2023Erum SalamBy Erum Salammore_vert
NBC NewsA new Alzheimer’s drug will cost $26,500 a year. Who will be able to get it?Jan 9, 2023Berkeley Lovelace & Berkeley Lovelace Jr.By Berkeley Lovelace & Berkeley Lovelace Jr.more_vert
The Washington PostAlzheimer's drug that slows cognitive decline gets FDA approvalJan 6, 2023Laurie McGinleyBy Laurie McGinleymore_vert
The Associated PressSpeedier drug approvals hit slowdown as FDA faces scrutinyDec 6, 2022Matthew PerroneBy Matthew Perronemore_vert
The Associated PressFDA panel urges rejection of experimental Alzheimer's drugNov 6, 2020Marilynn Marchione & Matthew PerroneBy Marilynn Marchione & Matthew Perronemore_vert
The Associated PressMedicare limits coverage of $28000-a-year Alzheimer's drugJan 11, 2022Ricardo S. AlonsoBy Ricardo S. Alonsomore_vert
The Associated PressFDA approves much-debated Alzheimer's drug panned by expertsJun 7, 2021Matthew PerroneBy Matthew Perronemore_vert
The Associated PressUS approves Alzheimer's drug that modestly slows diseaseJan 6, 2023Matthew PerroneBy Matthew Perronemore_vert
NBC NewsFDA approves new Alzheimer’s drug that appears to slow diseaseJan 6, 2023Berkeley Lovelace & Berkeley Lovelace Jr.By Berkeley Lovelace & Berkeley Lovelace Jr.more_vert
CNBCMost Alzheimer’s patients would pay up to $26,500 per year for new treatment LeqembiJan 9, 2023Spencer KimballBy Spencer Kimballmore_vert
NPRFDA grants Alzheimer's drug Leqembi accelerated approval : Shots - Health NewsJan 6, 2023Jon HamiltonBy Jon Hamiltonmore_vert